✦ LIBER ✦

Double-blind placebo-controlled DGAVP in early Alzheimer's disease patients

Book ID: 123197473
Publisher: Elsevier Science
Year: 1990
Tongue: English
Weight: 151 KB
Volume: 11
Category: Article
ISSN: 0197-4580
DOI: 10.1016/0197-4580(90)90944-U

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Double-blind placebo-controlled study of

Double-blind placebo-controlled study of velnacrine in Alzheimer's disease

✍ Frank P. Zemlan; Michael Keys; Ralph W. Richter; Richard L. Strub 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 672 KB

Donepezil in patients with severe Alzhei

Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study

✍ Bengt Winblad; Lena Kilander; Sture Eriksson; Lennart Minthon; Stellan Båtsman; 📂 Article 📅 2006 🏛 The Lancet 🌐 English ⚖ 169 KB

EARLY RESULTS FROM DOUBLE BLIND, PLACEBO

EARLY RESULTS FROM DOUBLE BLIND, PLACEBO CONTROLLED TRIAL OF HIGH DOSE PHOSPHATIDYLCHOLINE IN ALZHEIMER'S DISEASE

✍ Levy, Raymond; Little, Adrienne; Chuaqui, Paz; Reith, Margaret 📂 Article 📅 1983 🏛 The Lancet 🌐 English ⚖ 293 KB

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled trial with cerebrolysin in Alzheimer's disease

✍ M. Panisset; S. Gauthier; H. Moessler; M. Windisch 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 154 KB

A double-blind, placebo-controlled, enri

A double-blind, placebo-controlled, enriched population study of tacrine in patients with Alzheimer's disease

✍ F. Forette; T. Hoover; S. Gracon; J. de Rotrou; M.P. Hervy; B. Lechevalier; M. M 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 973 KB

A double-blind, placebo controlled, mult

A double-blind, placebo controlled, multicentre study of tacrine for alzheimer's disease

✍ Philip C. Wood; Professor C. Mark Castleden 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 527 KB

The present study was designed to determine whether oral tacrine (tetrahydroaminoacridine, THA) improves the symptoms of patients with mild to moderate Alzheimer's disease. The study was a multicentre, randomized doubleblind, placebo controlled, parallel group study with individual determination of